AM-Pharma is a biopharmaceutical company developing a biotherapeutic for the treatment of Acute Kidney Injury. The company initiated a 290 patient phase 2 study of recombinant human Alkaline Phosphatase in Acute Kidney Injury. Acute Kidney Injury is a major unmet medical need which involves an inflammatory process in the kidney which can lead to complete loss of renal function and affects annually around 2 million patients in Europe, US and Japan.
Gilde led an extension of the Series D round of €12.2M in November 2014 enabling the company to initiate and complete the phase 2 clincial study. In May 2015, Pfizer Inc. (NYSE: PFE) acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company for $87.5 million. Under the agreement, Pfizer will make additional potential payments of up to $512.5 million upon option exercise and potential launch of any product.
Bunnik, Utrecht, The Netherlands